替代供者造血干细胞移植治疗镰状细胞病
10例有症状的镰状细胞病患者接受来自不匹配家庭成员或无关供者的CD34+细胞精选、T细胞去除的外周血干细胞移植,采用包含美法仑、塞替派、氟达拉滨和兔抗胸腺细胞球蛋白的减低强度预处理方案。9/10例存活,中位随访49个月(范围14-60个月),存活患者供者造血植入稳定(平均供者嵌合率99.1%±0.7%),无移植后镰状细胞并发症;2例发生II-IV级急性GVHD,1例发生慢性GVHD,3例发生EB病毒相关移植后淋巴增殖性疾病(PTLD),其中1例死于PTLD治疗。2年总生存率90%,无事件生存率80%。
要点
- 10例患者均实现原发植入,9/10例存活,中位随访49个月。
- 2年总生存率90%,无事件生存率80%。
- 3例发生EB病毒相关PTLD,1例死于PTLD治疗。
核心结论
- 减低强度预处理后行CD34+细胞精选、T细胞去除的替代供者外周血干细胞移植在所有患者中实现原发植入,GVHD发生率低,但PTLD是个问题。
研究设计与样本
- 10例有症状的镰状细胞病患者接受来自不匹配家庭成员或无关供者的CD34+细胞精选、T细胞去除的外周血干细胞移植。
- 预处理方案为包含美法仑、塞替派、氟达拉滨和兔抗胸腺细胞球蛋白的减低强度方案。
- 患者筛选进入免疫重建伴随研究,该研究包括移植后30-42天给予供者淋巴细胞输注,并以静脉甲氨蝶呤预防移植物抗宿主病(GVHD);7例符合条件患者在伴随研究中接受治疗。
主要发现
- 10例患者中9例存活,中位随访49个月(范围14-60个月)。
- 存活患者供者造血植入稳定,平均供者嵌合率99.1%±0.7%。
- 移植后无镰状细胞并发症。
- 2例发生II-IV级急性GVHD,1例发生慢性GVHD。
- 3例发生EB病毒相关移植后淋巴增殖性疾病(PTLD),1例死于PTLD治疗。
关键数值与推荐
- 2年总生存率90%,无事件生存率80%。
- 平均供者嵌合率99.1%±0.7%。
- II-IV级急性GVHD 2例,慢性GVHD 1例,EB病毒相关PTLD 3例。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Most patients who could be cured of sickle cell disease (SCD) with stem cell transplantation do not have a matched sibling donor. Successful use of alternative donors, including mismatched family members, could provide a donor for almost all patients with SCD. The use of a reduced-intensity conditioning regimen may decrease late adverse effects. Ten patients with symptomatic SCD underwent CD34+ cell-selected, T-cell-depleted peripheral blood stem cell transplantation from a mismatched family member or unrelated donor. A reduced-intensity conditioning regimen including melphalan, thiotepa, fludarabine, and rabbit anti-thymocyte globulin was used. Patients were screened for a companion study for immune reconstitution that included a donor lymphocyte infusion given 30-42 days after transplant with intravenous methotrexate as graft-versus-host disease (GVHD) prophylaxis. Seven eligible patients were treated on the companion study. Nine of 10 patients are alive with a median follow-up of 49 months (range, 14-60 months). Surviving patients have stable donor hematopoietic engraftment (mean donor chimerism, 99.1% ± 0.7%). There were no sickle cell complications after transplant. Two patients had grade II-IV acute GVHD. One patient had chronic GVHD. Epstein-Barr virus-related posttransplant lymphoproliferative disorder (PTLD) occurred in 3 patients, and 1 patient died as a consequence of treatment of PTLD. Two-year overall survival was 90%, and event-free survival was 80%. A reduced-intensity conditioning regimen followed by CD34+ cell-selected, T-cell-depleted alternative donor peripheral blood stem cell transplantation achieved primary engraftment in all patients with a low incidence of GVHD, although PTLD was problematic. This trial was registered at clinicaltrials.gov as #NCT00968864.
引用
- Gilman AL, Eckrich MJ, Epstein S, et al. Alternative donor hematopoietic stem cell transplantation for sickle cell disease. Blood Adv. 2017. PMID: 29296761. doi:10.1182/bloodadvances.2017005462
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。